| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 22 | 2022 | 6915 | 2.020 |
Why?
|
| Protein Phosphatase 2 | 7 | 2018 | 88 | 1.780 |
Why?
|
| Galectin 3 | 3 | 2019 | 138 | 1.680 |
Why?
|
| Ceramides | 7 | 2016 | 95 | 1.300 |
Why?
|
| Tumor Microenvironment | 7 | 2018 | 2864 | 1.280 |
Why?
|
| Nitrophenols | 5 | 2021 | 92 | 1.190 |
Why?
|
| Apoptosis | 18 | 2022 | 7591 | 1.170 |
Why?
|
| Biphenyl Compounds | 5 | 2021 | 194 | 1.100 |
Why?
|
| Galectins | 4 | 2019 | 71 | 1.090 |
Why?
|
| Gene Expression Regulation, Leukemic | 7 | 2021 | 560 | 1.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 11 | 2016 | 1493 | 1.000 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 5 | 2022 | 275 | 0.890 |
Why?
|
| Drug Resistance, Neoplasm | 12 | 2022 | 5178 | 0.870 |
Why?
|
| c-Mer Tyrosine Kinase | 1 | 2022 | 23 | 0.860 |
Why?
|
| Sulfonamides | 6 | 2022 | 1823 | 0.800 |
Why?
|
| Phosphoprotein Phosphatases | 2 | 2018 | 214 | 0.770 |
Why?
|
| Galectin 1 | 1 | 2020 | 20 | 0.750 |
Why?
|
| CD27 Ligand | 1 | 2019 | 25 | 0.690 |
Why?
|
| Cell Death | 2 | 2021 | 671 | 0.680 |
Why?
|
| Immunologic Surveillance | 2 | 2015 | 60 | 0.680 |
Why?
|
| Immunity | 1 | 2021 | 342 | 0.660 |
Why?
|
| Stem Cell Niche | 1 | 2018 | 94 | 0.630 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 3 | 2008 | 301 | 0.600 |
Why?
|
| Virus Diseases | 1 | 2021 | 398 | 0.590 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2021 | 661 | 0.580 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 3 | 2022 | 923 | 0.570 |
Why?
|
| Protein Kinase Inhibitors | 7 | 2022 | 4757 | 0.570 |
Why?
|
| Glycogen Synthase Kinase 3 | 1 | 2017 | 161 | 0.570 |
Why?
|
| Phosphorylation | 13 | 2018 | 4804 | 0.560 |
Why?
|
| Signal Transduction | 13 | 2021 | 11965 | 0.540 |
Why?
|
| Naphthoquinones | 1 | 2015 | 18 | 0.530 |
Why?
|
| Gossypol | 1 | 2015 | 28 | 0.520 |
Why?
|
| Polysaccharides | 1 | 2015 | 197 | 0.500 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 5 | 2022 | 801 | 0.490 |
Why?
|
| Neoplastic Stem Cells | 4 | 2019 | 1443 | 0.490 |
Why?
|
| Up-Regulation | 4 | 2018 | 2450 | 0.460 |
Why?
|
| Cell Survival | 8 | 2020 | 3045 | 0.460 |
Why?
|
| Tumor Suppressor Protein p53 | 5 | 2020 | 3552 | 0.450 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 2054 | 0.440 |
Why?
|
| Cell Line, Tumor | 16 | 2022 | 14551 | 0.440 |
Why?
|
| Quinoxalines | 1 | 2012 | 95 | 0.410 |
Why?
|
| Imidazoles | 3 | 2016 | 999 | 0.400 |
Why?
|
| Leukemia | 2 | 2017 | 1635 | 0.390 |
Why?
|
| Protein Kinase C | 2 | 2011 | 396 | 0.390 |
Why?
|
| I-kappa B Kinase | 1 | 2012 | 250 | 0.390 |
Why?
|
| Inflammation | 2 | 2021 | 2522 | 0.360 |
Why?
|
| RNA, Small Interfering | 6 | 2020 | 2216 | 0.360 |
Why?
|
| THP-1 Cells | 2 | 2020 | 55 | 0.350 |
Why?
|
| Eukaryotic Initiation Factor-2B | 1 | 2008 | 8 | 0.340 |
Why?
|
| Mice, Inbred NOD | 4 | 2020 | 905 | 0.320 |
Why?
|
| Caspase 8 | 1 | 2008 | 145 | 0.320 |
Why?
|
| Piperazines | 8 | 2021 | 2101 | 0.320 |
Why?
|
| Neoplasm Proteins | 3 | 2020 | 3230 | 0.310 |
Why?
|
| MicroRNAs | 3 | 2020 | 2947 | 0.310 |
Why?
|
| Protein Interaction Maps | 2 | 2019 | 149 | 0.310 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2018 | 810 | 0.310 |
Why?
|
| Forkhead Transcription Factors | 1 | 2012 | 778 | 0.310 |
Why?
|
| Protein Kinase C-alpha | 3 | 2014 | 66 | 0.300 |
Why?
|
| eIF-2 Kinase | 1 | 2008 | 164 | 0.300 |
Why?
|
| Blood Proteins | 2 | 2019 | 294 | 0.300 |
Why?
|
| Kidney Tubules | 1 | 2007 | 137 | 0.290 |
Why?
|
| Humans | 48 | 2022 | 261506 | 0.290 |
Why?
|
| Antineoplastic Agents | 10 | 2021 | 14289 | 0.280 |
Why?
|
| Biomarkers, Tumor | 5 | 2019 | 10331 | 0.280 |
Why?
|
| Remission Induction | 2 | 2018 | 3569 | 0.280 |
Why?
|
| Cell Proliferation | 9 | 2021 | 7226 | 0.270 |
Why?
|
| Indoles | 1 | 2011 | 1009 | 0.260 |
Why?
|
| Caspases | 2 | 2007 | 661 | 0.260 |
Why?
|
| Animals | 19 | 2022 | 59536 | 0.260 |
Why?
|
| Mice, SCID | 3 | 2020 | 1869 | 0.260 |
Why?
|
| Neoplasms | 5 | 2021 | 15193 | 0.260 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 3 | 2019 | 2527 | 0.260 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 2 | 2022 | 460 | 0.250 |
Why?
|
| Proteomics | 3 | 2022 | 1380 | 0.250 |
Why?
|
| HL-60 Cells | 7 | 2016 | 302 | 0.250 |
Why?
|
| Ischemia | 1 | 2007 | 391 | 0.240 |
Why?
|
| Leukemia, Myeloid | 3 | 2018 | 941 | 0.240 |
Why?
|
| Xenograft Model Antitumor Assays | 5 | 2020 | 3821 | 0.230 |
Why?
|
| Autophagy | 3 | 2016 | 927 | 0.230 |
Why?
|
| Blotting, Western | 5 | 2015 | 3536 | 0.220 |
Why?
|
| Tumor Cells, Cultured | 6 | 2018 | 5395 | 0.220 |
Why?
|
| Mitochondria | 6 | 2016 | 1282 | 0.200 |
Why?
|
| Bone Marrow | 2 | 2020 | 2358 | 0.200 |
Why?
|
| Prognosis | 7 | 2021 | 21713 | 0.190 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2021 | 51 | 0.190 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2021 | 163 | 0.190 |
Why?
|
| Gene Ontology | 1 | 2020 | 80 | 0.190 |
Why?
|
| Adenylate Kinase | 2 | 2021 | 36 | 0.180 |
Why?
|
| Protein-Tyrosine Kinases | 2 | 2018 | 1756 | 0.180 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2015 | 2488 | 0.180 |
Why?
|
| Mice | 13 | 2022 | 34495 | 0.180 |
Why?
|
| Metals, Heavy | 1 | 2020 | 32 | 0.180 |
Why?
|
| Plasminogen Activator Inhibitor 1 | 1 | 2020 | 65 | 0.180 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2020 | 8873 | 0.180 |
Why?
|
| RNA Splicing Factors | 1 | 2020 | 153 | 0.170 |
Why?
|
| Bortezomib | 1 | 2021 | 543 | 0.170 |
Why?
|
| Coculture Techniques | 2 | 2018 | 626 | 0.170 |
Why?
|
| Peptide Fragments | 2 | 2015 | 1271 | 0.170 |
Why?
|
| Protein Kinases | 1 | 2003 | 874 | 0.170 |
Why?
|
| Cell Line | 5 | 2017 | 5114 | 0.160 |
Why?
|
| Protein Interaction Mapping | 1 | 2019 | 162 | 0.160 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2018 | 59 | 0.160 |
Why?
|
| Protein Phosphatase 1 | 1 | 2018 | 79 | 0.160 |
Why?
|
| Molecular Targeted Therapy | 2 | 2021 | 2330 | 0.160 |
Why?
|
| Spleen | 1 | 2020 | 676 | 0.160 |
Why?
|
| Cell Growth Processes | 1 | 2018 | 342 | 0.160 |
Why?
|
| Antagomirs | 1 | 2016 | 19 | 0.150 |
Why?
|
| Microscopy, Fluorescence | 3 | 2013 | 769 | 0.150 |
Why?
|
| Tandem Repeat Sequences | 1 | 2017 | 201 | 0.150 |
Why?
|
| Dietary Supplements | 1 | 2021 | 558 | 0.140 |
Why?
|
| Protein Transport | 4 | 2018 | 734 | 0.140 |
Why?
|
| Autophagy-Related Protein 7 | 1 | 2016 | 33 | 0.140 |
Why?
|
| Drug Synergism | 2 | 2018 | 1313 | 0.140 |
Why?
|
| Mutation | 4 | 2021 | 15179 | 0.140 |
Why?
|
| Activating Transcription Factor 4 | 1 | 2016 | 73 | 0.130 |
Why?
|
| Models, Immunological | 1 | 2015 | 77 | 0.130 |
Why?
|
| Cell Adhesion | 2 | 2015 | 1008 | 0.130 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 2 | 2008 | 334 | 0.130 |
Why?
|
| Protein Array Analysis | 1 | 2018 | 501 | 0.130 |
Why?
|
| Flow Cytometry | 4 | 2015 | 3033 | 0.130 |
Why?
|
| Wnt Signaling Pathway | 1 | 2018 | 430 | 0.130 |
Why?
|
| Heterocyclic Compounds, 4 or More Rings | 1 | 2016 | 119 | 0.130 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6207 | 0.130 |
Why?
|
| Heterografts | 1 | 2017 | 733 | 0.130 |
Why?
|
| Blood Platelets | 2 | 2013 | 731 | 0.130 |
Why?
|
| Oleanolic Acid | 2 | 2008 | 108 | 0.130 |
Why?
|
| Cell Hypoxia | 1 | 2015 | 328 | 0.130 |
Why?
|
| Gene Regulatory Networks | 1 | 2019 | 677 | 0.130 |
Why?
|
| Protein Isoforms | 1 | 2017 | 842 | 0.120 |
Why?
|
| bcl-X Protein | 3 | 2021 | 196 | 0.120 |
Why?
|
| Propylene Glycols | 1 | 2014 | 36 | 0.120 |
Why?
|
| Sphingosine | 1 | 2014 | 55 | 0.120 |
Why?
|
| Fingolimod Hydrochloride | 1 | 2014 | 45 | 0.120 |
Why?
|
| Phosphoproteins | 1 | 2020 | 1152 | 0.120 |
Why?
|
| Tumor Burden | 1 | 2020 | 1987 | 0.120 |
Why?
|
| Epigenesis, Genetic | 1 | 2021 | 1399 | 0.120 |
Why?
|
| Integrin alpha4beta1 | 1 | 2014 | 45 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2015 | 1764 | 0.120 |
Why?
|
| Immunoprecipitation | 1 | 2015 | 591 | 0.120 |
Why?
|
| Cell Differentiation | 3 | 2018 | 4078 | 0.120 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2014 | 121 | 0.120 |
Why?
|
| Etoposide | 2 | 2008 | 870 | 0.120 |
Why?
|
| Carcinogenesis | 1 | 2020 | 1026 | 0.120 |
Why?
|
| K562 Cells | 2 | 2016 | 338 | 0.110 |
Why?
|
| Benzimidazoles | 1 | 2016 | 428 | 0.110 |
Why?
|
| beta Catenin | 1 | 2017 | 688 | 0.110 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 1 | 2014 | 146 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 1 | 2015 | 1165 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 2 | 2021 | 5061 | 0.110 |
Why?
|
| Hypoxia | 1 | 2015 | 443 | 0.110 |
Why?
|
| Cell Communication | 1 | 2015 | 509 | 0.110 |
Why?
|
| ras Proteins | 1 | 2017 | 770 | 0.110 |
Why?
|
| Computational Biology | 1 | 2019 | 1271 | 0.110 |
Why?
|
| RNA, Messenger | 2 | 2020 | 6150 | 0.110 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 507 | 0.100 |
Why?
|
| Platelet Aggregation | 1 | 2013 | 257 | 0.100 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 986 | 0.100 |
Why?
|
| Male | 11 | 2021 | 123000 | 0.100 |
Why?
|
| Protein Kinase C beta | 1 | 2011 | 35 | 0.100 |
Why?
|
| src-Family Kinases | 1 | 2014 | 478 | 0.100 |
Why?
|
| Fusion Proteins, bcr-abl | 3 | 2019 | 1094 | 0.100 |
Why?
|
| Lung Neoplasms | 3 | 2016 | 11538 | 0.100 |
Why?
|
| Sp3 Transcription Factor | 1 | 2010 | 13 | 0.100 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 1 | 2011 | 212 | 0.100 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 2359 | 0.100 |
Why?
|
| Piperidines | 1 | 2016 | 1035 | 0.100 |
Why?
|
| Berberine | 2 | 2021 | 12 | 0.100 |
Why?
|
| Neovascularization, Physiologic | 1 | 2013 | 345 | 0.100 |
Why?
|
| Female | 13 | 2021 | 141928 | 0.090 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2017 | 1678 | 0.090 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2016 | 713 | 0.090 |
Why?
|
| Neoplasm Metastasis | 2 | 2021 | 5112 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2018 | 10035 | 0.090 |
Why?
|
| Sp1 Transcription Factor | 1 | 2010 | 188 | 0.090 |
Why?
|
| Antigens, CD34 | 1 | 2011 | 593 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2010 | 2022 | 0.090 |
Why?
|
| Severity of Illness Index | 1 | 2020 | 4320 | 0.090 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2021 | 2390 | 0.080 |
Why?
|
| Kava | 1 | 2008 | 9 | 0.080 |
Why?
|
| Bcl-2-Like Protein 11 | 2 | 2007 | 65 | 0.080 |
Why?
|
| Proto-Oncogene Proteins c-raf | 1 | 2008 | 80 | 0.080 |
Why?
|
| Cell Cycle Proteins | 1 | 2017 | 2045 | 0.080 |
Why?
|
| Stem Cells | 1 | 2015 | 1213 | 0.080 |
Why?
|
| p21-Activated Kinases | 1 | 2008 | 122 | 0.080 |
Why?
|
| Aged | 6 | 2021 | 70117 | 0.080 |
Why?
|
| Middle Aged | 7 | 2021 | 86204 | 0.080 |
Why?
|
| Rats | 3 | 2007 | 6086 | 0.080 |
Why?
|
| DNA Damage | 1 | 2016 | 1954 | 0.080 |
Why?
|
| Imatinib Mesylate | 2 | 2008 | 1665 | 0.080 |
Why?
|
| NF-kappa B | 1 | 2014 | 1549 | 0.070 |
Why?
|
| Amino Acid Substitution | 1 | 2008 | 644 | 0.070 |
Why?
|
| Plant Extracts | 1 | 2008 | 215 | 0.070 |
Why?
|
| Protein Kinase C-delta | 1 | 2006 | 42 | 0.070 |
Why?
|
| Benzamides | 2 | 2008 | 1832 | 0.070 |
Why?
|
| Dimerization | 2 | 2006 | 304 | 0.070 |
Why?
|
| Survival Analysis | 1 | 2017 | 9180 | 0.070 |
Why?
|
| Salvage Therapy | 1 | 2014 | 2054 | 0.070 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2013 | 1248 | 0.070 |
Why?
|
| Apoptosis Regulatory Proteins | 2 | 2007 | 621 | 0.070 |
Why?
|
| Enzyme Inhibitors | 1 | 2013 | 1879 | 0.070 |
Why?
|
| Models, Biological | 1 | 2014 | 3254 | 0.060 |
Why?
|
| Aged, 80 and over | 4 | 2020 | 29902 | 0.060 |
Why?
|
| Lipopolysaccharides | 1 | 2007 | 558 | 0.060 |
Why?
|
| Hematologic Neoplasms | 1 | 2016 | 1870 | 0.060 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2008 | 852 | 0.060 |
Why?
|
| Active Transport, Cell Nucleus | 1 | 2004 | 323 | 0.060 |
Why?
|
| Adenoma | 1 | 2008 | 716 | 0.060 |
Why?
|
| Cell Physiological Phenomena | 1 | 2003 | 24 | 0.060 |
Why?
|
| Pyrimidines | 3 | 2016 | 3518 | 0.060 |
Why?
|
| Enzymes | 1 | 2003 | 64 | 0.060 |
Why?
|
| Mutation, Missense | 1 | 2008 | 1152 | 0.060 |
Why?
|
| Nitric Oxide | 1 | 2007 | 644 | 0.060 |
Why?
|
| Aldehyde Reductase | 1 | 2003 | 60 | 0.060 |
Why?
|
| Cell Cycle | 3 | 2018 | 2084 | 0.060 |
Why?
|
| Protein Structure, Tertiary | 2 | 2006 | 1487 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2014 | 5159 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2007 | 1144 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2010 | 3154 | 0.050 |
Why?
|
| Breast Neoplasms | 3 | 2021 | 15694 | 0.050 |
Why?
|
| Precipitin Tests | 1 | 2002 | 329 | 0.050 |
Why?
|
| Adult | 5 | 2020 | 77950 | 0.050 |
Why?
|
| Subcellular Fractions | 1 | 2002 | 201 | 0.050 |
Why?
|
| Gene Silencing | 2 | 2018 | 837 | 0.050 |
Why?
|
| Stromal Cells | 2 | 2016 | 825 | 0.050 |
Why?
|
| Thiadiazoles | 1 | 2021 | 47 | 0.050 |
Why?
|
| Tumor Stem Cell Assay | 1 | 2021 | 231 | 0.050 |
Why?
|
| Catalytic Domain | 1 | 2002 | 303 | 0.050 |
Why?
|
| Inhibitory Concentration 50 | 1 | 2021 | 289 | 0.050 |
Why?
|
| Immunoglobulin Heavy Chains | 1 | 2021 | 247 | 0.050 |
Why?
|
| Macrophages | 1 | 2007 | 1304 | 0.050 |
Why?
|
| bcl-2-Associated X Protein | 3 | 2007 | 367 | 0.050 |
Why?
|
| Malaria | 1 | 2021 | 92 | 0.050 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1618 | 0.050 |
Why?
|
| Trace Elements | 1 | 2020 | 33 | 0.050 |
Why?
|
| Protein Binding | 2 | 2008 | 3438 | 0.050 |
Why?
|
| Plasmids | 1 | 2002 | 837 | 0.050 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2014 | 503 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 4938 | 0.040 |
Why?
|
| MCF-7 Cells | 1 | 2021 | 550 | 0.040 |
Why?
|
| Case-Control Studies | 2 | 2020 | 6100 | 0.040 |
Why?
|
| Immunohistochemistry | 2 | 2018 | 7548 | 0.040 |
Why?
|
| Cell Membrane | 1 | 2002 | 850 | 0.040 |
Why?
|
| Glycolysis | 1 | 2021 | 519 | 0.040 |
Why?
|
| Point Mutation | 1 | 2021 | 769 | 0.040 |
Why?
|
| Cells, Cultured | 3 | 2014 | 5637 | 0.040 |
Why?
|
| Gene Duplication | 1 | 2020 | 421 | 0.040 |
Why?
|
| Membrane Proteins | 2 | 2007 | 2819 | 0.040 |
Why?
|
| Mass Spectrometry | 1 | 2020 | 702 | 0.040 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2018 | 15862 | 0.040 |
Why?
|
| Metformin | 1 | 2021 | 378 | 0.040 |
Why?
|
| Transfection | 1 | 2002 | 2944 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2021 | 1944 | 0.040 |
Why?
|
| Dynamins | 1 | 2016 | 74 | 0.040 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2016 | 234 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2021 | 1353 | 0.030 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 252 | 0.030 |
Why?
|
| Lentivirus | 1 | 2015 | 169 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 2796 | 0.030 |
Why?
|
| Acute Disease | 2 | 2014 | 2422 | 0.030 |
Why?
|
| GTP Phosphohydrolases | 1 | 2016 | 336 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2021 | 1960 | 0.030 |
Why?
|
| Mitochondrial Proteins | 1 | 2016 | 369 | 0.030 |
Why?
|
| U937 Cells | 1 | 2014 | 171 | 0.030 |
Why?
|
| Doxorubicin | 1 | 2021 | 3005 | 0.030 |
Why?
|
| Pruritus | 1 | 2014 | 87 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 2014 | 394 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2016 | 534 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 663 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2016 | 1077 | 0.030 |
Why?
|
| Thrombospondin 1 | 1 | 2013 | 55 | 0.030 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2008 | 639 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2018 | 2292 | 0.030 |
Why?
|
| Cytoplasmic Granules | 1 | 2013 | 89 | 0.030 |
Why?
|
| Aniline Compounds | 1 | 2013 | 177 | 0.030 |
Why?
|
| Immunoblotting | 1 | 2014 | 886 | 0.030 |
Why?
|
| Transcriptome | 1 | 2021 | 1859 | 0.030 |
Why?
|
| Diabetes Mellitus | 1 | 2021 | 1054 | 0.030 |
Why?
|
| Cell Movement | 1 | 2020 | 2466 | 0.030 |
Why?
|
| Exanthema | 1 | 2014 | 211 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2010 | 51 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2014 | 619 | 0.020 |
Why?
|
| Biopsy | 1 | 2018 | 3443 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 2013 | 750 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2013 | 598 | 0.020 |
Why?
|
| Administration, Oral | 1 | 2014 | 1544 | 0.020 |
Why?
|
| Disease Progression | 1 | 2021 | 6682 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2013 | 1489 | 0.020 |
Why?
|
| Collagen | 1 | 2013 | 752 | 0.020 |
Why?
|
| Cisplatin | 1 | 2016 | 2432 | 0.020 |
Why?
|
| Chemoradiotherapy | 1 | 2018 | 1946 | 0.020 |
Why?
|
| Benzo(a)pyrene | 1 | 2008 | 35 | 0.020 |
Why?
|
| Nitrosamines | 1 | 2008 | 50 | 0.020 |
Why?
|
| Pyridines | 1 | 2016 | 1244 | 0.020 |
Why?
|
| Phosphoserine | 1 | 2008 | 107 | 0.020 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 3343 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2014 | 1048 | 0.020 |
Why?
|
| Chemoprevention | 1 | 2008 | 241 | 0.020 |
Why?
|
| HeLa Cells | 1 | 2010 | 1643 | 0.020 |
Why?
|
| Epidermal Growth Factor | 1 | 2008 | 423 | 0.020 |
Why?
|
| bcl-2 Homologous Antagonist-Killer Protein | 1 | 2006 | 72 | 0.020 |
Why?
|
| Cytarabine | 2 | 2004 | 1973 | 0.020 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2013 | 1533 | 0.020 |
Why?
|
| Oxidation-Reduction | 1 | 2008 | 717 | 0.020 |
Why?
|
| HEK293 Cells | 1 | 2010 | 1489 | 0.020 |
Why?
|
| Eating | 1 | 2008 | 421 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2007 | 261 | 0.020 |
Why?
|
| Disease-Free Survival | 1 | 2018 | 10001 | 0.020 |
Why?
|
| Treatment Outcome | 2 | 2020 | 32848 | 0.020 |
Why?
|
| Caco-2 Cells | 1 | 2006 | 158 | 0.020 |
Why?
|
| Infant | 1 | 2021 | 13310 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2008 | 703 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2008 | 551 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2018 | 7222 | 0.020 |
Why?
|
| Child, Preschool | 1 | 2021 | 16273 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12221 | 0.020 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 4233 | 0.020 |
Why?
|
| Base Sequence | 1 | 2010 | 4917 | 0.010 |
Why?
|
| Body Weight | 1 | 2008 | 1293 | 0.010 |
Why?
|
| Oxygen | 1 | 2008 | 754 | 0.010 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1546 | 0.010 |
Why?
|
| Protein Conformation | 1 | 2006 | 1258 | 0.010 |
Why?
|
| Phosphorus Radioisotopes | 1 | 2003 | 44 | 0.010 |
Why?
|
| Bryostatins | 1 | 2003 | 12 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2010 | 3101 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 6089 | 0.010 |
Why?
|
| Reactive Oxygen Species | 1 | 2008 | 987 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2018 | 14889 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2003 | 108 | 0.010 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 2003 | 226 | 0.010 |
Why?
|
| Macrolides | 1 | 2003 | 62 | 0.010 |
Why?
|
| Lactones | 1 | 2003 | 94 | 0.010 |
Why?
|
| COS Cells | 1 | 2003 | 377 | 0.010 |
Why?
|
| Adenocarcinoma | 1 | 2021 | 7789 | 0.010 |
Why?
|
| Annexin A5 | 1 | 2002 | 72 | 0.010 |
Why?
|
| Substrate Specificity | 1 | 2003 | 549 | 0.010 |
Why?
|
| DNA Fragmentation | 1 | 2002 | 198 | 0.010 |
Why?
|
| Retinoids | 1 | 2002 | 164 | 0.010 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 1555 | 0.010 |
Why?
|
| Muscle, Smooth, Vascular | 1 | 2003 | 330 | 0.010 |
Why?
|
| Caspase 3 | 1 | 2002 | 471 | 0.010 |
Why?
|
| Membrane Potentials | 1 | 2002 | 424 | 0.010 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2006 | 1242 | 0.010 |
Why?
|
| Drug Interactions | 1 | 2002 | 553 | 0.010 |
Why?
|
| Child | 1 | 2021 | 29154 | 0.010 |
Why?
|
| Young Adult | 1 | 2018 | 21445 | 0.010 |
Why?
|
| Tretinoin | 1 | 2002 | 623 | 0.010 |
Why?
|
| Blast Crisis | 1 | 2002 | 557 | 0.010 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 3981 | 0.010 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2004 | 1299 | 0.010 |
Why?
|
| Algorithms | 1 | 2008 | 3890 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2003 | 2927 | 0.010 |
Why?
|